SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-208807
Filing Date
2020-08-04
Accepted
2020-08-04 08:30:51
Documents
2
Group Members
PIVOTAL BIOVENTURE PARTNER FUND I G.P., L.P.PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D d930194dsc13d.htm SC 13D 88076
2 EXHIBIT 1 d930194dex991.htm EX-99.1 8433
  Complete submission text file 0001193125-20-208807.txt   98347
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91586 | Film No.: 201071036
SIC: 2834 Pharmaceutical Preparations

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (345) 949 1040
Pivotal bioVenture Partners Fund I, L.P. (Filed by) CIK: 0001695076 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: SC 13D